Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro

Jingwei Xie, Jan C.M. Marijnissen, Chi Hwa Wang

Research output: Contribution to journalArticle

163 Citations (Scopus)

Abstract

This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma in vitro. Controllable morphologies such as spheres, donut shapes and corrugated shapes with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy (SEM) and field emission electron microscope (FSEM). The differential scanning calorimetry (DSC) study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The X-ray photoelectron spectroscopy (XPS) result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80% and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol® in the long-term in vitro tests evaluated by MTS assay. The drug delivery devices developed by EHDA in this study could be promising for the local drug delivery to treat malignant glioma.

Original languageEnglish (US)
Pages (from-to)3321-3332
Number of pages12
JournalBiomaterials
Volume27
Issue number17
DOIs
StatePublished - Jun 1 2006

Fingerprint

Electrohydrodynamics
Atomization
Paclitaxel
Glioma
Drug delivery
Encapsulation
Field emission microscopes
Pharmaceutical Preparations
Cytotoxicity
Polymer matrix
Differential scanning calorimetry
Solid solutions
Assays
Electron microscopes
X ray photoelectron spectroscopy
Crystalline materials
Fabrication
Photoelectron Spectroscopy
Scanning electron microscopy
G2 Phase

Keywords

  • Biodegradable
  • Cytotoxicity
  • Electrohydrodynamic atomization
  • Microparticle
  • Paclitaxel

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro. / Xie, Jingwei; Marijnissen, Jan C.M.; Wang, Chi Hwa.

In: Biomaterials, Vol. 27, No. 17, 01.06.2006, p. 3321-3332.

Research output: Contribution to journalArticle

@article{b150a73cddea43e2b5109475b02953bc,
title = "Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro",
abstract = "This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma in vitro. Controllable morphologies such as spheres, donut shapes and corrugated shapes with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy (SEM) and field emission electron microscope (FSEM). The differential scanning calorimetry (DSC) study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The X-ray photoelectron spectroscopy (XPS) result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80{\%} and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol{\circledR} in the long-term in vitro tests evaluated by MTS assay. The drug delivery devices developed by EHDA in this study could be promising for the local drug delivery to treat malignant glioma.",
keywords = "Biodegradable, Cytotoxicity, Electrohydrodynamic atomization, Microparticle, Paclitaxel",
author = "Jingwei Xie and Marijnissen, {Jan C.M.} and Wang, {Chi Hwa}",
year = "2006",
month = "6",
day = "1",
doi = "10.1016/j.biomaterials.2006.01.034",
language = "English (US)",
volume = "27",
pages = "3321--3332",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "17",

}

TY - JOUR

T1 - Microparticles developed by electrohydrodynamic atomization for the local delivery of anticancer drug to treat C6 glioma in vitro

AU - Xie, Jingwei

AU - Marijnissen, Jan C.M.

AU - Wang, Chi Hwa

PY - 2006/6/1

Y1 - 2006/6/1

N2 - This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma in vitro. Controllable morphologies such as spheres, donut shapes and corrugated shapes with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy (SEM) and field emission electron microscope (FSEM). The differential scanning calorimetry (DSC) study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The X-ray photoelectron spectroscopy (XPS) result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80% and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol® in the long-term in vitro tests evaluated by MTS assay. The drug delivery devices developed by EHDA in this study could be promising for the local drug delivery to treat malignant glioma.

AB - This study aims to fabricate biodegradable polymeric particles by electrohydrodynamic atomization (EHDA) for applications in sustained delivery of anticancer drug - paclitaxel to treat C6 glioma in vitro. Controllable morphologies such as spheres, donut shapes and corrugated shapes with sizes from several tens of microns to hundred nanometers of particles were observed by scanning electron microscopy (SEM) and field emission electron microscope (FSEM). The differential scanning calorimetry (DSC) study indicated that paclitaxel could be either in an amorphous or disordered-crystalline phase of a molecular dispersion or a solid solution state in the polymer matrix after fabrication. The X-ray photoelectron spectroscopy (XPS) result suggested that some amount of paclitaxel could exist on the surface layer of the microparticles. The encapsulation efficiency was around 80% and more than 30 days in vitro sustained release profile could be achieved. Cell cycling results suggested that paclitaxel after encapsulation by EHDA could keep its biological function and inhibit C6 glioma cells in G2/M phase. The cytotoxicity of paclitaxel-loaded biodegradable microparticles to C6 glioma cells could be higher than Taxol® in the long-term in vitro tests evaluated by MTS assay. The drug delivery devices developed by EHDA in this study could be promising for the local drug delivery to treat malignant glioma.

KW - Biodegradable

KW - Cytotoxicity

KW - Electrohydrodynamic atomization

KW - Microparticle

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=33644758226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644758226&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2006.01.034

DO - 10.1016/j.biomaterials.2006.01.034

M3 - Article

C2 - 16490248

AN - SCOPUS:33644758226

VL - 27

SP - 3321

EP - 3332

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 17

ER -